<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02115815</url>
  </required_header>
  <id_info>
    <org_study_id>CD-VA-MEDI7510-1134</org_study_id>
    <secondary_id>BB-IND 15947</secondary_id>
    <nct_id>NCT02115815</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety of the Respiratory Syncytial Virus Vaccine MEDI7510 in Older Adults</brief_title>
  <official_title>A Phase 1a Study to Evaluate the Safety of the Respiratory Syncytial Virus Vaccine MEDI7510 in Older Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the administration of single ascending
      intramuscular doses of the RSV sF antigen or MEDI7510 will be safe and well tolerated in
      adults 60 years or older who are healthy or who have stable, chronic underlying medical
      conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase 1a, first time in human, double-blind, randomized, placebo-controlled, cohort
      escalation study evaluating the safety and tolerability of a single ascending intramuscular
      dose of RSV sF or MEDI7510 or placebo.

      Approximately 146 participants will be enrolled at 3 US study centers and randomized in a 5:1
      ratio by cohort as described below:

      Cohort 1: RSV sF 20 microgram (mcg) (n=20) or placebo (n=4) Cohort 1a: MEDI7510 (20 mcg RSV
      sF with 2.5 mcg glucopyranosyl lipid A (GLA) + 2% weight per volume stable emulsion (n=20) or
      placebo (n=4) Cohort 2: RSV sF 50 mcg (n=20) or placebo (n=4) Cohort 2a: MEDI7510 (50 mcg RSV
      sF with 2.5 mcg glucopyranosyl lipid A (GLA) + 2% weight per volume stable emulsion (n=20) or
      placebo (n=4) Cohort 3: 80 mcg RSV sF (n=20) or placebo (n=4) Cohort 3a: MEDI7510 (80 mcg RSV
      sF with 2.5 mcg glucopyranosyl lipid A (GLA) + 2% weight per volume stable emulsion (n=20) or
      placebo (n=4)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Solicited Symptoms</measure>
    <time_frame>Day 1 to Day 7</time_frame>
    <description>Solicited symptoms: tenderness or soreness at site of injection, pain at site of injection, fatigue or tiredness, headache, generalized muscle aches, swelling at the site of injection, redness at the site of injection, fever greater than or equal to (&gt;=) 100.4 degrees F by any route from Day 1 to Day 7.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)</measure>
    <time_frame>From Day 1 to Day 28</time_frame>
    <description>An adverse event (AE) was any untoward medical occurrence attributed to study drug in a participant who received investigational product. A serious adverse event (SAE) was an AE resulting in any of following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between administration of study product and Day 361 that were absent before treatment or that worsened relative to pretreatment state.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events of Special Interest (TEAESIs), Treatment-Emergent Serious Adverse Events (TESAEs) and Treatment-Emergent New Onset Chronic Disease (NOCDs)</measure>
    <time_frame>From Day 1 to Day 361</time_frame>
    <description>An adverse event (AE) was any untoward medical occurrence attributed to study drug in a participant who received investigational product. A serious adverse event (SAE) was an AE resulting in any of following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between administration of study product and Day 361 that were absent before treatment or that worsened relative to pretreatment state. An AESI was one of scientific and medical interest specific to understanding of study product and may have required close monitoring and rapid communication by investigator to the sponsor. A NOCD was a newly diagnosed medical condition that is of a chronic, ongoing nature. It was observed after receiving investigational product and was assessed by investigator as medically significant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-dose Geometric Mean Titers (GMTs) From Baseline of Serum Antibodies Against Respiratory Syncytial Virus (RSV) by RSV A Microneutralization Assay</measure>
    <time_frame>Baseline (Day 1), Day 29, 61, 91, 181, 271 and 361</time_frame>
    <description>RSV neutralizing antibody titers were measured using green fluorescent protein tagged RSV A 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-dose Geometric Mean Fold Rises (GMFRs) From Baseline of Serum Antibodies Against Respiratory Syncytial Virus (RSV) by RSV A Microneutralization Assay</measure>
    <time_frame>Day 29, 61, 91, 181, 271 and 361</time_frame>
    <description>RSV neutralizing antibody titers were measured using green fluorescent protein tagged RSV A 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Experience a Post-dose Seroresponse to Respiratory Syncytial Virus (RSV) by RSV A Microneutralization Assay</measure>
    <time_frame>Day 29</time_frame>
    <description>Seroresponse defined as a greater than or equal to (&gt;=) 4-fold rise from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-dose Geometric Mean Titers (GMTs) From Baseline of Serum Antibodies Against Respiratory Syncytial Virus (RSV) by Anti-Fusion Protein (F) Immunoglobulin G (IgG) Assay</measure>
    <time_frame>Baseline (Day 1), Day 29, 61, 91, 181, 271 and 361</time_frame>
    <description>Anti F IgG antibodies were determined by a multiplex IgG assay developed on the Meso Scale discovery platform.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-dose Geometric Mean Fold Rises (GMFRs) From Baseline of Serum Antibodies Against Respiratory Syncytial Virus (RSV) by Anti-Fusion Protein (F) Immunoglobulin G (IgG) Assay</measure>
    <time_frame>Day 29, 61, 91, 181, 271 and 361</time_frame>
    <description>Anti F IgG antibodies were determined by a multiplex IgG assay developed on the Meso Scale discovery platform.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Experience a Post-dose Seroresponse to Respiratory Syncytial Virus (RSV) by Anti-Fusion Protein (F) Immunoglobulin G (IgG) Assay</measure>
    <time_frame>Day 29</time_frame>
    <description>Seroresponse defined as a greater than or equal to (&gt;=) 4-fold rise from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-dose Geometric Mean Counts (GMCs) From Baseline of T Cell Response Against Respiratory Syncytial Virus (RSV) by RSV F Enzyme-Linked Immunospot (ELISPOT)</measure>
    <time_frame>Baseline (Day 1), Day 8 and 29</time_frame>
    <description>The ELISPOT assay for F protein-specific gamma interferon-producing T cells was performed using RSV F peptides.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-dose Geometric Mean Fold Rises (GMFRs) of T Cell Response Against Respiratory Syncytial Virus (RSV) by RSV F Enzyme-Linked Immunospot (ELISPOT)</measure>
    <time_frame>Day 8 and 29</time_frame>
    <description>The ELISPOT assay for F protein-specific gamma interferon-producing T cells was performed using RSV F peptides.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Experience a Post-dose 3-fold Cell-mediated Immune Response to RSV F on Day 8</measure>
    <time_frame>Day 8</time_frame>
    <description>Seroresponse defined as a greater than or equal to (&gt;=) 3-fold rise from baseline</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">246</enrollment>
  <condition>Respiratory Syncytial Virus (RSV)</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sterile saline for human use from commercial source, liquid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RSV sF 20 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive single dose of 20 mcg RSV sF by intramuscular injection on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI7510 (20 mcg RSV sF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive single dose of MEDI7510 (20 mcg RSV sF with 2.5 mcg glucopyranosyl lipid A [GLA] + 2% weight per volume stable emulsion) by intramuscular injection on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RSV sF 50 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive single dose of 50 mcg RSV sF by intramuscular injection on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI7510 (50 mcg RSV sF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive single dose of MEDI7510 (50 mcg RSV sF with 2.5 mcg GLA + 2% weight per volume stable emulsion) by intramuscular injection on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RSV sF 80 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive single dose of 80 mcg RSV sF by intramuscular injection on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI7510 (80 mcg RSV sF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of MEDI7510 (80 mcg RSV sF with 2.5 mcg GLA + 2% weight per volume stable emulsion) by intramuscular injection on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive placebo (sterile saline for human use from commercial source liquid) on Day 1.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RSV sF 20 mcg</intervention_name>
    <description>Participants will receive single dose of 20 mcg RSV sF by intramuscular injection on Day 1.</description>
    <arm_group_label>RSV sF 20 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI7510 (20 mcg RSV sF)</intervention_name>
    <description>Participants will receive single dose of MEDI7510 containing 20 mcg RSV sF by intramuscular injection on Day 1.</description>
    <arm_group_label>MEDI7510 (20 mcg RSV sF)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RSV sF 50 mcg</intervention_name>
    <description>Participants will receive single dose of 50 mcg RSV sF by intramuscular injection on Day 1.</description>
    <arm_group_label>RSV sF 50 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI7510 (50 mcg RSV sF)</intervention_name>
    <description>Participants will receive single dose of MEDI7510 containing 50 mcg RSV sF by intramuscular injection on Day 1.</description>
    <arm_group_label>MEDI7510 (50 mcg RSV sF)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RSV sF 80 mcg</intervention_name>
    <description>Participants will receive single dose of 80 mcg RSV sF by intramuscular injection on Day 1.</description>
    <arm_group_label>RSV sF 80 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI7510 (80 mcg RSV sF)</intervention_name>
    <description>Participants will receive single dose of MEDI7510 containing 80 mcg RSV sF by intramuscular injection on Day 1.</description>
    <arm_group_label>MEDI7510 (80 mcg RSV sF)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age greater than or equal to 60 years

          -  Written informed consent and any locally required authorization obtained prior to any
             protocol related procedures

          -  Ambulatory or ambulatory with assistance (not institutionalized, bedridden, or
             homebound

          -  Weight at or above 110 Pounds (lbs)

          -  Hemoglobin within normal range for age and gender

        Exclusion Criteria:

          -  History of allergy to any component of the vaccine

          -  Pregnancy or potential to become pregnant during the study. Females who have had a
             menstrual period within the 12 months prior to study enrollment or are undergoing any
             fertility treatment or who plan to undergo fertility treatments during the study
             period are excluded

          -  Any unstable chronic medical condition, including one that has resulted in change in
             therapy (medication or other) in the 30 days prior to randomization or hospitalization
             in the previous year or might be predicted to result in hospitalization in the year
             after enrollment. Participant with severe, untreated or uncontrolled underlying
             medical disease that might either compromise participant safety or affect the ability
             to assess safety of the investigational product are excluded

          -  Clinically significant abnormalities in Screening laboratory assessments or Screening
             electrocardiogram (ECG)

          -  History of hepatitis B or hepatitis C infection

          -  Cognitive disorder such that informed consent cannot be obtained directly from the
             participant

          -  Previous vaccination against respiratory syncytial virus (RSV)

          -  History of allergy to eggs in adulthood

          -  History of or current autoimmune disorder

          -  Immunosuppression caused by disease, including human immunodeficiency virus (HIV), or
             medications. Any oral prednisone dosing within 30 days of enrollment or planned dosing
             within the 360-day follow-up period would disqualify.

          -  History of splenectomy or of condition affecting splenic function

          -  History of cancer within preceding 5 years other than treated non-melanoma skin cancer

          -  Body Mass Index 40 or higher

          -  Significant infection or other acute illness, including fever over 100 fahrenheit (F)
             on the day prior to or day of randomization

          -  Receipt of any nonstudy vaccine within 30 days prior to study dosing or expected
             receipt of nonstudy vaccine within 30 days after study dosing

          -  Receipt of any investigational product in the 90 days prior to randomization or
             expected receipt of investigational product during the period of study follow-up

          -  Receipt of immunoglobulins or blood products within 4 months of study dosing (120
             days) or expected receipt of investigational product during the period of study
             follow-up

          -  History of thrombocytopenia or bleeding disorder or use of anticoagulants.
             Participants receiving drugs with anti-platelet activity such as nonsteroidal
             antiinflammatory drugs, clopidogrel or aspirin are not excluded

          -  Expected receipt of antipyretic or analgesic medication on a daily or every other day
             basis from randomization through 72 hours after receipt of investigational product
             (IP) [a daily dose of 163 milligram (mg) or higher is not considered a
             contraindication to enrollment]

          -  Participants who have significant scarring, tattoos, abrasions, cuts, or infections
             over the deltoid region of both arms that, in the principle investigator's (PI)
             opinion, could interfere with evaluation of injection site local reactions

          -  Concurrent enrollment in another clinical study that involves any invasive clinical
             procedure, including phlebotomy

          -  History of alcohol or drug abuse or psychiatric disorder that in the PI's opinion
             would affect the participants safety or compliance with study

          -  Employees of individuals directly involved with the conduct of the study, individuals
             who themselves are involved with the conduct of the study, or immediate family members
             of such individuals.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Sheldon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Miami Research Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Craig Curtis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Compass Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven Bart, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Accelovance</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Judith Falloon, MD</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Miami Research Associates</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compass Research</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accelovance, Inc</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=2490&amp;filename=MEDI7510-1134_Protocol_Legal%20IP_Redacted_04.05.16.pdf</url>
    <description>CD-VA-MEDI7510-1134 Redacted Protocol</description>
  </link>
  <results_reference>
    <citation>Falloon J, Ji F, Curtis C, Bart S, Sheldon E, Krieger D, Dubovsky F, Lambert S, Takas T, Villafana T, Esser MT. A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant. Vaccine. 2016 May 27;34(25):2847-54. doi: 10.1016/j.vaccine.2016.04.002. Epub 2016 Apr 19.</citation>
    <PMID>27102821</PMID>
  </results_reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2014</study_first_submitted>
  <study_first_submitted_qc>April 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2014</study_first_posted>
  <results_first_submitted>July 15, 2016</results_first_submitted>
  <results_first_submitted_qc>August 29, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 21, 2016</results_first_posted>
  <last_update_submitted>August 29, 2016</last_update_submitted>
  <last_update_submitted_qc>August 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Respiratory Syncytial Virus (RSV)</keyword>
  <keyword>MEDI7510</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 246 subjects were screened. Of these, 146 subjects were enrolled.</recruitment_details>
      <pre_assignment_details>A total of 146 participants were enrolled in the study. Of the 146 randomized participants, 2 participants did not receive investigational product. 144 participants were included in the As-treated Population.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants received placebo (sterile saline for human use from commercial source, liquid) by intramuscular injection on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>RSV sF 20 Microgram (mcg)</title>
          <description>Participants received single dose of 20 mcg RSV sF by intramuscular injection on Day 1.</description>
        </group>
        <group group_id="P3">
          <title>MEDI7510 20 Microgram (mcg)</title>
          <description>Participants received single dose of MEDI7510 (20 mcg RSV sF with 2.5 mcg glucopyranosyl lipid A [GLA] + 2% weight per volume stable emulsion) by intramuscular injection on Day 1.</description>
        </group>
        <group group_id="P4">
          <title>RSV sF 50 Microgram (mcg)</title>
          <description>Participants received single dose of 50 mcg RSV sF by intramuscular injection on Day 1.</description>
        </group>
        <group group_id="P5">
          <title>MEDI7510 50 Microgram (mcg)</title>
          <description>Participants received single dose of MEDI7510 (50 mcg RSV sF with 2.5 mcg GLA in 2% weight per volume stable emulsion) by intramuscular injection on Day 1.</description>
        </group>
        <group group_id="P6">
          <title>RSV sF 80 Microgram (mcg)</title>
          <description>Participants received single dose of 80 mcg RSV sF by intramuscular injection on Day 1.</description>
        </group>
        <group group_id="P7">
          <title>MEDI7510 80 Microgram (mcg)</title>
          <description>Participants received single dose of MEDI7510 (80 mcg RSV sF with 2.5 mcg GLA in 2% weight per volume stable emulsion) by intramuscular injection on Day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="20"/>
                <participants group_id="P5" count="20"/>
                <participants group_id="P6" count="22"/>
                <participants group_id="P7" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="20"/>
                <participants group_id="P5" count="20"/>
                <participants group_id="P6" count="20"/>
                <participants group_id="P7" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not enough drug to dose participant</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missed appointment, randomized in error</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>As-treated Population (ATP): Participants who received any study investigational product were included in the ATP population.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received placebo (sterile saline for human use from commercial source, liquid) by intramuscular injection on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>RSV sF 20 Microgram (mcg)</title>
          <description>Participants received single dose of 20 mcg RSV sF by intramuscular injection on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>MEDI7510 20 Microgram (mcg)</title>
          <description>Participants received single dose of MEDI7510 (20 mcg RSV sF with 2.5 mcg glucopyranosyl lipid A [GLA] + 2% weight per volume stable emulsion) by intramuscular injection on Day 1.</description>
        </group>
        <group group_id="B4">
          <title>RSV sF 50 Microgram (mcg)</title>
          <description>Participants received single dose of 50 mcg RSV sF by intramuscular injection on Day 1.</description>
        </group>
        <group group_id="B5">
          <title>MEDI7510 50 Microgram (mcg)</title>
          <description>Participants received single dose of MEDI7510 (50 mcg RSV sF with 2.5 mcg GLA in 2% weight per volume stable emulsion) by intramuscular injection on Day 1.</description>
        </group>
        <group group_id="B6">
          <title>RSV sF 80 Microgram (mcg)</title>
          <description>Participants received single dose of 80 mcg RSV sF by intramuscular injection on Day 1.</description>
        </group>
        <group group_id="B7">
          <title>MEDI7510 80 Microgram (mcg)</title>
          <description>Participants received single dose of MEDI7510 (80 mcg RSV sF with 2.5 mcg GLA in 2% weight per volume stable emulsion) by intramuscular injection on Day 1.</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="20"/>
            <count group_id="B4" value="20"/>
            <count group_id="B5" value="20"/>
            <count group_id="B6" value="20"/>
            <count group_id="B7" value="20"/>
            <count group_id="B8" value="144"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.6" spread="7.6"/>
                    <measurement group_id="B2" value="66.5" spread="6.0"/>
                    <measurement group_id="B3" value="66.6" spread="4.1"/>
                    <measurement group_id="B4" value="69.3" spread="5.6"/>
                    <measurement group_id="B5" value="70.5" spread="6.1"/>
                    <measurement group_id="B6" value="70.0" spread="7.0"/>
                    <measurement group_id="B7" value="69.4" spread="7.0"/>
                    <measurement group_id="B8" value="68.7" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="11"/>
                    <measurement group_id="B8" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="9"/>
                    <measurement group_id="B8" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Solicited Symptoms</title>
        <description>Solicited symptoms: tenderness or soreness at site of injection, pain at site of injection, fatigue or tiredness, headache, generalized muscle aches, swelling at the site of injection, redness at the site of injection, fever greater than or equal to (&gt;=) 100.4 degrees F by any route from Day 1 to Day 7.</description>
        <time_frame>Day 1 to Day 7</time_frame>
        <population>As-treated Population (ATP) included participants who received any study investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo (sterile saline for human use from commercial source, liquid) by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>RSV sF 20 Microgram (mcg)</title>
            <description>Participants received single dose of 20 mcg RSV sF by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI7510 20 Microgram (mcg)</title>
            <description>Participants received single dose of MEDI7510 (20 mcg RSV sF with 2.5 mcg glucopyranosyl lipid A [GLA] + 2% weight per volume stable emulsion) by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>RSV sF 50 Microgram (mcg)</title>
            <description>Participants received single dose of 50 mcg RSV sF by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI7510 50 Microgram (mcg)</title>
            <description>Participants received single dose of MEDI7510 (50 mcg RSV sF with 2.5 mcg GLA in 2% weight per volume stable emulsion) by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>RSV sF 80 Microgram (mcg)</title>
            <description>Participants received single dose of 80 mcg RSV sF by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>MEDI7510 80 Microgram (mcg)</title>
            <description>Participants received single dose of MEDI7510 (80 mcg RSV sF with 2.5 mcg GLA in 2% weight per volume stable emulsion) by intramuscular injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Solicited Symptoms</title>
          <description>Solicited symptoms: tenderness or soreness at site of injection, pain at site of injection, fatigue or tiredness, headache, generalized muscle aches, swelling at the site of injection, redness at the site of injection, fever greater than or equal to (&gt;=) 100.4 degrees F by any route from Day 1 to Day 7.</description>
          <population>As-treated Population (ATP) included participants who received any study investigational product.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)</title>
        <description>An adverse event (AE) was any untoward medical occurrence attributed to study drug in a participant who received investigational product. A serious adverse event (SAE) was an AE resulting in any of following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between administration of study product and Day 361 that were absent before treatment or that worsened relative to pretreatment state.</description>
        <time_frame>From Day 1 to Day 28</time_frame>
        <population>As-treated Population (ATP) included participants who received any study investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo (sterile saline for human use from commercial source, liquid) by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>RSV sF 20 Microgram (mcg)</title>
            <description>Participants received single dose of 20 mcg RSV sF by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI7510 20 Microgram (mcg)</title>
            <description>Participants received single dose of MEDI7510 (20 mcg RSV sF with 2.5 mcg glucopyranosyl lipid A [GLA] + 2% weight per volume stable emulsion) by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>RSV sF 50 Microgram (mcg)</title>
            <description>Participants received single dose of 50 mcg RSV sF by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI7510 50 Microgram (mcg)</title>
            <description>Participants received single dose of MEDI7510 (50 mcg RSV sF with 2.5 mcg GLA in 2% weight per volume stable emulsion) by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>RSV sF 80 Microgram (mcg)</title>
            <description>Participants received single dose of 80 mcg RSV sF by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>MEDI7510 80 Microgram (mcg)</title>
            <description>Participants received single dose of MEDI7510 (80 mcg RSV sF with 2.5 mcg GLA in 2% weight per volume stable emulsion) by intramuscular injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)</title>
          <description>An adverse event (AE) was any untoward medical occurrence attributed to study drug in a participant who received investigational product. A serious adverse event (SAE) was an AE resulting in any of following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between administration of study product and Day 361 that were absent before treatment or that worsened relative to pretreatment state.</description>
          <population>As-treated Population (ATP) included participants who received any study investigational product.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TESAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events of Special Interest (TEAESIs), Treatment-Emergent Serious Adverse Events (TESAEs) and Treatment-Emergent New Onset Chronic Disease (NOCDs)</title>
        <description>An adverse event (AE) was any untoward medical occurrence attributed to study drug in a participant who received investigational product. A serious adverse event (SAE) was an AE resulting in any of following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between administration of study product and Day 361 that were absent before treatment or that worsened relative to pretreatment state. An AESI was one of scientific and medical interest specific to understanding of study product and may have required close monitoring and rapid communication by investigator to the sponsor. A NOCD was a newly diagnosed medical condition that is of a chronic, ongoing nature. It was observed after receiving investigational product and was assessed by investigator as medically significant.</description>
        <time_frame>From Day 1 to Day 361</time_frame>
        <population>As-treated Population (ATP) included participants who received any study investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo (sterile saline for human use from commercial source, liquid) by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>RSV sF 20 Microgram (mcg)</title>
            <description>Participants received single dose of 20 mcg RSV sF by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI7510 20 Microgram (mcg)</title>
            <description>Participants received single dose of MEDI7510 (20 mcg RSV sF with 2.5 mcg glucopyranosyl lipid A [GLA] + 2% weight per volume stable emulsion) by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>RSV sF 50 Microgram (mcg)</title>
            <description>Participants received single dose of 50 mcg RSV sF by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI7510 50 Microgram (mcg)</title>
            <description>Participants received single dose of MEDI7510 (50 mcg RSV sF with 2.5 mcg GLA in 2% weight per volume stable emulsion) by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>RSV sF 80 Microgram (mcg)</title>
            <description>Participants received single dose of 80 mcg RSV sF by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>MEDI7510 80 Microgram (mcg)</title>
            <description>Participants received single dose of MEDI7510 (80 mcg RSV sF with 2.5 mcg GLA in 2% weight per volume stable emulsion) by intramuscular injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events of Special Interest (TEAESIs), Treatment-Emergent Serious Adverse Events (TESAEs) and Treatment-Emergent New Onset Chronic Disease (NOCDs)</title>
          <description>An adverse event (AE) was any untoward medical occurrence attributed to study drug in a participant who received investigational product. A serious adverse event (SAE) was an AE resulting in any of following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between administration of study product and Day 361 that were absent before treatment or that worsened relative to pretreatment state. An AESI was one of scientific and medical interest specific to understanding of study product and may have required close monitoring and rapid communication by investigator to the sponsor. A NOCD was a newly diagnosed medical condition that is of a chronic, ongoing nature. It was observed after receiving investigational product and was assessed by investigator as medically significant.</description>
          <population>As-treated Population (ATP) included participants who received any study investigational product.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAESIs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TESAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NOCDs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-dose Geometric Mean Titers (GMTs) From Baseline of Serum Antibodies Against Respiratory Syncytial Virus (RSV) by RSV A Microneutralization Assay</title>
        <description>RSV neutralizing antibody titers were measured using green fluorescent protein tagged RSV A 2</description>
        <time_frame>Baseline (Day 1), Day 29, 61, 91, 181, 271 and 361</time_frame>
        <population>Immunogenicity population included participants in the As-treated population who had no protocol deviation judged to have the potential to interfere with the generation or interpretation of an immune response, and had baseline and/or any post-baseline result. Here, &quot;n&quot; is number of participants analysed for this outcome measure at give time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo (sterile saline for human use from commercial source, liquid) by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>RSV sF 20 Microgram (mcg)</title>
            <description>Participants received single dose of 20 mcg RSV sF by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI7510 20 Microgram (mcg)</title>
            <description>Participants received single dose of MEDI7510 (20 mcg RSV sF with 2.5 mcg glucopyranosyl lipid A [GLA] + 2% weight per volume stable emulsion) by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>RSV sF 50 Microgram (mcg)</title>
            <description>Participants received single dose of 50 mcg RSV sF by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI7510 50 Microgram (mcg)</title>
            <description>Participants received single dose of MEDI7510 (50 mcg RSV sF with 2.5 mcg GLA in 2% weight per volume stable emulsion) by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>RSV sF 80 Microgram (mcg)</title>
            <description>Participants received single dose of 80 mcg RSV sF by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>MEDI7510 80 Microgram (mcg)</title>
            <description>Participants received single dose of MEDI7510 (80 mcg RSV sF with 2.5 mcg GLA in 2% weight per volume stable emulsion) by intramuscular injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Post-dose Geometric Mean Titers (GMTs) From Baseline of Serum Antibodies Against Respiratory Syncytial Virus (RSV) by RSV A Microneutralization Assay</title>
          <description>RSV neutralizing antibody titers were measured using green fluorescent protein tagged RSV A 2</description>
          <population>Immunogenicity population included participants in the As-treated population who had no protocol deviation judged to have the potential to interfere with the generation or interpretation of an immune response, and had baseline and/or any post-baseline result. Here, &quot;n&quot; is number of participants analysed for this outcome measure at give time points.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n= 24, 20, 20, 20, 20, 20, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="441.37" lower_limit="293.36" upper_limit="664.05"/>
                    <measurement group_id="O2" value="362.67" lower_limit="252.96" upper_limit="519.95"/>
                    <measurement group_id="O3" value="367.73" lower_limit="220.44" upper_limit="613.44"/>
                    <measurement group_id="O4" value="448.36" lower_limit="282.62" upper_limit="711.28"/>
                    <measurement group_id="O5" value="442.03" lower_limit="294.25" upper_limit="664.02"/>
                    <measurement group_id="O6" value="491.31" lower_limit="327.84" upper_limit="736.30"/>
                    <measurement group_id="O7" value="428.16" lower_limit="334.37" upper_limit="548.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (n= 24, 20, 20, 20, 19, 19, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="430.04" lower_limit="285.59" upper_limit="647.56"/>
                    <measurement group_id="O2" value="619.09" lower_limit="419.12" upper_limit="914.45"/>
                    <measurement group_id="O3" value="809.84" lower_limit="611.36" upper_limit="1072.77"/>
                    <measurement group_id="O4" value="981.61" lower_limit="695.95" upper_limit="1384.51"/>
                    <measurement group_id="O5" value="1182.72" lower_limit="813.02" upper_limit="1720.53"/>
                    <measurement group_id="O6" value="1116.48" lower_limit="813.79" upper_limit="1531.74"/>
                    <measurement group_id="O7" value="1405.14" lower_limit="1079.32" upper_limit="1829.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 61 (n= 24, 20, 20, 20, 20, 20, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="513.18" lower_limit="339.82" upper_limit="775.00"/>
                    <measurement group_id="O2" value="716.09" lower_limit="455.53" upper_limit="1125.70"/>
                    <measurement group_id="O3" value="764.04" lower_limit="563.35" upper_limit="1036.21"/>
                    <measurement group_id="O4" value="959.74" lower_limit="693.89" upper_limit="1327.44"/>
                    <measurement group_id="O5" value="1092.18" lower_limit="769.39" upper_limit="1550.40"/>
                    <measurement group_id="O6" value="945.22" lower_limit="732.16" upper_limit="1220.28"/>
                    <measurement group_id="O7" value="1046.60" lower_limit="802.46" upper_limit="1365.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 91 (n= 23, 20, 20, 19, 20, 19, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="535.19" lower_limit="350.79" upper_limit="816.54"/>
                    <measurement group_id="O2" value="635.83" lower_limit="417.05" upper_limit="969.37"/>
                    <measurement group_id="O3" value="641.14" lower_limit="464.88" upper_limit="884.24"/>
                    <measurement group_id="O4" value="849.22" lower_limit="582.14" upper_limit="1238.85"/>
                    <measurement group_id="O5" value="1013.06" lower_limit="700.41" upper_limit="1465.27"/>
                    <measurement group_id="O6" value="834.48" lower_limit="626.96" upper_limit="1110.69"/>
                    <measurement group_id="O7" value="992.21" lower_limit="799.35" upper_limit="1231.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 181 (n= 23, 19, 20, 19, 20, 18, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="373.79" lower_limit="238.19" upper_limit="586.60"/>
                    <measurement group_id="O2" value="419.68" lower_limit="281.38" upper_limit="625.97"/>
                    <measurement group_id="O3" value="421.09" lower_limit="276.97" upper_limit="640.22"/>
                    <measurement group_id="O4" value="548.95" lower_limit="372.94" upper_limit="808.01"/>
                    <measurement group_id="O5" value="487.07" lower_limit="328.42" upper_limit="722.38"/>
                    <measurement group_id="O6" value="761.54" lower_limit="558.06" upper_limit="1039.21"/>
                    <measurement group_id="O7" value="614.39" lower_limit="435.55" upper_limit="866.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 271 (n= 20, 20, 20, 19, 20, 17, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="485.89" lower_limit="325.78" upper_limit="724.69"/>
                    <measurement group_id="O2" value="600.28" lower_limit="441.76" upper_limit="815.70"/>
                    <measurement group_id="O3" value="589.97" lower_limit="418.92" upper_limit="830.86"/>
                    <measurement group_id="O4" value="829.32" lower_limit="592.46" upper_limit="1160.89"/>
                    <measurement group_id="O5" value="710.41" lower_limit="498.88" upper_limit="1011.61"/>
                    <measurement group_id="O6" value="705.14" lower_limit="522.45" upper_limit="951.71"/>
                    <measurement group_id="O7" value="560.89" lower_limit="360.47" upper_limit="872.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 361 (n= 18, 0, 0, 0, 0, 17, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="491.90" lower_limit="313.90" upper_limit="770.85"/>
                    <measurement group_id="O2" value="NA">No participants were evaluated.</measurement>
                    <measurement group_id="O3" value="NA">No participants were evaluated.</measurement>
                    <measurement group_id="O4" value="NA">No participants were evaluated.</measurement>
                    <measurement group_id="O5" value="NA">No participants were evaluated.</measurement>
                    <measurement group_id="O6" value="675.04" lower_limit="503.39" upper_limit="905.21"/>
                    <measurement group_id="O7" value="483.15" lower_limit="360.07" upper_limit="648.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-dose Geometric Mean Fold Rises (GMFRs) From Baseline of Serum Antibodies Against Respiratory Syncytial Virus (RSV) by RSV A Microneutralization Assay</title>
        <description>RSV neutralizing antibody titers were measured using green fluorescent protein tagged RSV A 2.</description>
        <time_frame>Day 29, 61, 91, 181, 271 and 361</time_frame>
        <population>Immunogenicity population included participants in the As-treated population who had no protocol deviation judged to have the potential to interfere with the generation or interpretation of an immune response, and had baseline and/or any post-baseline result. Here, &quot;n&quot; is number of participants analysed for this outcome measure at give time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo (sterile saline for human use from commercial source, liquid) by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>RSV sF 20 Microgram (mcg)</title>
            <description>Participants received single dose of 20 mcg RSV sF by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI7510 20 Microgram (mcg)</title>
            <description>Participants received single dose of MEDI7510 (20 mcg RSV sF with 2.5 mcg glucopyranosyl lipid A [GLA] + 2% weight per volume stable emulsion) by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>RSV sF 50 Microgram (mcg)</title>
            <description>Participants received single dose of 50 mcg RSV sF by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI7510 50 Microgram (mcg)</title>
            <description>Participants received single dose of MEDI7510 (50 mcg RSV sF with 2.5 mcg GLA in 2% weight per volume stable emulsion) by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>RSV sF 80 Microgram (mcg)</title>
            <description>Participants received single dose of 80 mcg RSV sF by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>MEDI7510 80 Microgram (mcg)</title>
            <description>Participants received single dose of MEDI7510 (80 mcg RSV sF with 2.5 mcg GLA in 2% weight per volume stable emulsion) by intramuscular injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Post-dose Geometric Mean Fold Rises (GMFRs) From Baseline of Serum Antibodies Against Respiratory Syncytial Virus (RSV) by RSV A Microneutralization Assay</title>
          <description>RSV neutralizing antibody titers were measured using green fluorescent protein tagged RSV A 2.</description>
          <population>Immunogenicity population included participants in the As-treated population who had no protocol deviation judged to have the potential to interfere with the generation or interpretation of an immune response, and had baseline and/or any post-baseline result. Here, &quot;n&quot; is number of participants analysed for this outcome measure at give time points.</population>
          <units>fold rise</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 29 (n= 24, 20, 20, 20, 19, 19, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" lower_limit="0.89" upper_limit="1.07"/>
                    <measurement group_id="O2" value="1.71" lower_limit="1.34" upper_limit="2.17"/>
                    <measurement group_id="O3" value="2.20" lower_limit="1.43" upper_limit="3.39"/>
                    <measurement group_id="O4" value="2.19" lower_limit="1.52" upper_limit="3.15"/>
                    <measurement group_id="O5" value="2.53" lower_limit="1.85" upper_limit="3.46"/>
                    <measurement group_id="O6" value="2.51" lower_limit="1.74" upper_limit="3.62"/>
                    <measurement group_id="O7" value="3.28" lower_limit="2.51" upper_limit="4.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 61 (n= 24, 20, 20, 20, 20, 20, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.16" lower_limit="0.95" upper_limit="1.42"/>
                    <measurement group_id="O2" value="1.97" lower_limit="1.50" upper_limit="2.60"/>
                    <measurement group_id="O3" value="2.08" lower_limit="1.33" upper_limit="3.25"/>
                    <measurement group_id="O4" value="2.14" lower_limit="1.46" upper_limit="3.14"/>
                    <measurement group_id="O5" value="2.47" lower_limit="1.74" upper_limit="3.51"/>
                    <measurement group_id="O6" value="1.92" lower_limit="1.32" upper_limit="2.80"/>
                    <measurement group_id="O7" value="2.44" lower_limit="1.88" upper_limit="3.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 91 (n= 23, 20, 20, 19, 20, 19, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.18" lower_limit="0.99" upper_limit="1.39"/>
                    <measurement group_id="O2" value="1.75" lower_limit="1.40" upper_limit="2.20"/>
                    <measurement group_id="O3" value="1.74" lower_limit="1.14" upper_limit="2.67"/>
                    <measurement group_id="O4" value="2.01" lower_limit="1.38" upper_limit="2.92"/>
                    <measurement group_id="O5" value="2.29" lower_limit="1.65" upper_limit="3.18"/>
                    <measurement group_id="O6" value="1.72" lower_limit="1.18" upper_limit="2.51"/>
                    <measurement group_id="O7" value="2.32" lower_limit="1.82" upper_limit="2.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 181 (n= 23, 19, 20, 19, 20, 18, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.82" lower_limit="0.72" upper_limit="0.94"/>
                    <measurement group_id="O2" value="1.13" lower_limit="0.93" upper_limit="1.38"/>
                    <measurement group_id="O3" value="1.15" lower_limit="0.69" upper_limit="1.90"/>
                    <measurement group_id="O4" value="1.30" lower_limit="0.96" upper_limit="1.75"/>
                    <measurement group_id="O5" value="1.10" lower_limit="0.89" upper_limit="1.37"/>
                    <measurement group_id="O6" value="1.50" lower_limit="0.96" upper_limit="2.33"/>
                    <measurement group_id="O7" value="1.43" lower_limit="1.10" upper_limit="1.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 271 (n= 20, 20, 20, 19, 20, 17, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.87" lower_limit="0.76" upper_limit="0.99"/>
                    <measurement group_id="O2" value="1.66" lower_limit="1.38" upper_limit="1.98"/>
                    <measurement group_id="O3" value="1.60" lower_limit="1.02" upper_limit="2.53"/>
                    <measurement group_id="O4" value="1.96" lower_limit="1.50" upper_limit="2.56"/>
                    <measurement group_id="O5" value="1.61" lower_limit="1.29" upper_limit="2.00"/>
                    <measurement group_id="O6" value="1.38" lower_limit="0.90" upper_limit="2.09"/>
                    <measurement group_id="O7" value="1.32" lower_limit="0.89" upper_limit="1.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 361 (n= 7, 0, 0, 0, 0, 17, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" lower_limit="0.58" upper_limit="0.91"/>
                    <measurement group_id="O2" value="NA">No participant was evaluated.</measurement>
                    <measurement group_id="O3" value="NA">No participant was evaluated.</measurement>
                    <measurement group_id="O4" value="NA">No participant was evaluated.</measurement>
                    <measurement group_id="O5" value="NA">No participant was evaluated.</measurement>
                    <measurement group_id="O6" value="1.32" lower_limit="0.87" upper_limit="2.01"/>
                    <measurement group_id="O7" value="1.14" lower_limit="0.91" upper_limit="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Experience a Post-dose Seroresponse to Respiratory Syncytial Virus (RSV) by RSV A Microneutralization Assay</title>
        <description>Seroresponse defined as a greater than or equal to (&gt;=) 4-fold rise from baseline.</description>
        <time_frame>Day 29</time_frame>
        <population>Immunogenicity population included participants in the As-treated population who had no protocol deviation judged to have the potential to interfere with the generation or interpretation of an immune response, and had baseline and/or any post-baseline result.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo (sterile saline for human use from commercial source, liquid) by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>RSV sF 20 Microgram (mcg)</title>
            <description>Participants received single dose of 20 mcg RSV sF by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI7510 20 Microgram (mcg)</title>
            <description>Participants received single dose of MEDI7510 (20 mcg RSV sF with 2.5 mcg glucopyranosyl lipid A [GLA] + 2% weight per volume stable emulsion) by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>RSV sF 50 Microgram (mcg)</title>
            <description>Participants received single dose of 50 mcg RSV sF by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI7510 50 Microgram (mcg)</title>
            <description>Participants received single dose of MEDI7510 (50 mcg RSV sF with 2.5 mcg GLA in 2% weight per volume stable emulsion) by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>RSV sF 80 Microgram (mcg)</title>
            <description>Participants received single dose of 80 mcg RSV sF by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>MEDI7510 80 Microgram (mcg)</title>
            <description>Participants received single dose of MEDI7510 (80 mcg RSV sF with 2.5 mcg GLA in 2% weight per volume stable emulsion) by intramuscular injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experience a Post-dose Seroresponse to Respiratory Syncytial Virus (RSV) by RSV A Microneutralization Assay</title>
          <description>Seroresponse defined as a greater than or equal to (&gt;=) 4-fold rise from baseline.</description>
          <population>Immunogenicity population included participants in the As-treated population who had no protocol deviation judged to have the potential to interfere with the generation or interpretation of an immune response, and had baseline and/or any post-baseline result.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="19"/>
                <count group_id="O6" value="19"/>
                <count group_id="O7" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.00" upper_limit="14.25"/>
                    <measurement group_id="O2" value="10.0" lower_limit="1.23" upper_limit="31.70"/>
                    <measurement group_id="O3" value="5.0" lower_limit="0.13" upper_limit="24.87"/>
                    <measurement group_id="O4" value="5.0" lower_limit="0.13" upper_limit="24.87"/>
                    <measurement group_id="O5" value="10.5" lower_limit="1.30" upper_limit="33.14"/>
                    <measurement group_id="O6" value="26.3" lower_limit="9.15" upper_limit="51.20"/>
                    <measurement group_id="O7" value="25.0" lower_limit="8.66" upper_limit="49.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-dose Geometric Mean Titers (GMTs) From Baseline of Serum Antibodies Against Respiratory Syncytial Virus (RSV) by Anti-Fusion Protein (F) Immunoglobulin G (IgG) Assay</title>
        <description>Anti F IgG antibodies were determined by a multiplex IgG assay developed on the Meso Scale discovery platform.</description>
        <time_frame>Baseline (Day 1), Day 29, 61, 91, 181, 271 and 361</time_frame>
        <population>Immunogenicity population included participants in ATP who had no protocol deviation judged to have potential to interfere with generation or interpretation of an immune response, and had baseline and/or any post-baseline result. Here, &quot;n&quot; is number of participants analysed for this outcome measure at give time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo (sterile saline for human use from commercial source, liquid) by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>RSV sF 20 Microgram (mcg)</title>
            <description>Participants received single dose of 20 mcg RSV sF by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI7510 20 Microgram (mcg)</title>
            <description>Participants received single dose of MEDI7510 (20 mcg RSV sF with 2.5 mcg glucopyranosyl lipid A [GLA] + 2% weight per volume stable emulsion) by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>RSV sF 50 Microgram (mcg)</title>
            <description>Participants received single dose of 50 mcg RSV sF by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI7510 50 Microgram (mcg)</title>
            <description>Participants received single dose of MEDI7510 (50 mcg RSV sF with 2.5 mcg GLA in 2% weight per volume stable emulsion) by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>RSV sF 80 Microgram (mcg)</title>
            <description>Participants received single dose of 80 mcg RSV sF by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>MEDI7510 80 Microgram (mcg)</title>
            <description>Participants received single dose of MEDI7510 (80 mcg RSV sF with 2.5 mcg GLA in 2% weight per volume stable emulsion) by intramuscular injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Post-dose Geometric Mean Titers (GMTs) From Baseline of Serum Antibodies Against Respiratory Syncytial Virus (RSV) by Anti-Fusion Protein (F) Immunoglobulin G (IgG) Assay</title>
          <description>Anti F IgG antibodies were determined by a multiplex IgG assay developed on the Meso Scale discovery platform.</description>
          <population>Immunogenicity population included participants in ATP who had no protocol deviation judged to have potential to interfere with generation or interpretation of an immune response, and had baseline and/or any post-baseline result. Here, &quot;n&quot; is number of participants analysed for this outcome measure at give time points.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n= 24, 20, 20, 20, 20, 20, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.89" lower_limit="46.32" upper_limit="90.90"/>
                    <measurement group_id="O2" value="45.24" lower_limit="30.89" upper_limit="66.26"/>
                    <measurement group_id="O3" value="64.94" lower_limit="44.56" upper_limit="94.63"/>
                    <measurement group_id="O4" value="82.73" lower_limit="44.45" upper_limit="153.97"/>
                    <measurement group_id="O5" value="93.51" lower_limit="61.85" upper_limit="141.38"/>
                    <measurement group_id="O6" value="76.61" lower_limit="45.39" upper_limit="129.29"/>
                    <measurement group_id="O7" value="73.84" lower_limit="48.14" upper_limit="113.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (n= 24, 20, 20, 20, 20, 19, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.16" lower_limit="47.46" upper_limit="92.24"/>
                    <measurement group_id="O2" value="364.83" lower_limit="214.31" upper_limit="621.05"/>
                    <measurement group_id="O3" value="658.97" lower_limit="460.21" upper_limit="943.58"/>
                    <measurement group_id="O4" value="998.28" lower_limit="636.44" upper_limit="1565.84"/>
                    <measurement group_id="O5" value="1159.03" lower_limit="773.42" upper_limit="1736.89"/>
                    <measurement group_id="O6" value="924.44" lower_limit="598.78" upper_limit="1427.22"/>
                    <measurement group_id="O7" value="1552.03" lower_limit="1162.56" upper_limit="2071.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 61 (n= 24, 20, 20, 20, 20, 20, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.76" lower_limit="53.17" upper_limit="96.85"/>
                    <measurement group_id="O2" value="351.98" lower_limit="208.53" upper_limit="594.11"/>
                    <measurement group_id="O3" value="454.40" lower_limit="316.95" upper_limit="651.45"/>
                    <measurement group_id="O4" value="738.48" lower_limit="481.62" upper_limit="1132.34"/>
                    <measurement group_id="O5" value="875.86" lower_limit="609.86" upper_limit="1257.88"/>
                    <measurement group_id="O6" value="731.83" lower_limit="478.07" upper_limit="1120.28"/>
                    <measurement group_id="O7" value="1136.41" lower_limit="834.01" upper_limit="1548.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 91 (n= 22, 20, 20, 19, 20, 19, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.57" lower_limit="51.15" upper_limit="100.14"/>
                    <measurement group_id="O2" value="305.06" lower_limit="184.64" upper_limit="504.02"/>
                    <measurement group_id="O3" value="365.38" lower_limit="256.55" upper_limit="520.39"/>
                    <measurement group_id="O4" value="587.79" lower_limit="376.03" upper_limit="918.81"/>
                    <measurement group_id="O5" value="704.64" lower_limit="478.10" upper_limit="1038.52"/>
                    <measurement group_id="O6" value="596.80" lower_limit="385.76" upper_limit="923.30"/>
                    <measurement group_id="O7" value="928.58" lower_limit="675.84" upper_limit="1275.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 181 (n= 23, 19, 20, 19, 20, 18, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.41" lower_limit="49.68" upper_limit="94.19"/>
                    <measurement group_id="O2" value="211.75" lower_limit="134.85" upper_limit="332.50"/>
                    <measurement group_id="O3" value="235.81" lower_limit="163.36" upper_limit="340.38"/>
                    <measurement group_id="O4" value="405.25" lower_limit="252.75" upper_limit="649.78"/>
                    <measurement group_id="O5" value="456.76" lower_limit="311.64" upper_limit="669.46"/>
                    <measurement group_id="O6" value="463.64" lower_limit="311.06" upper_limit="691.06"/>
                    <measurement group_id="O7" value="604.90" lower_limit="429.19" upper_limit="852.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 271 (n= 20, 20, 20, 19, 20, 17, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.65" lower_limit="59.58" upper_limit="103.82"/>
                    <measurement group_id="O2" value="170.78" lower_limit="116.92" upper_limit="249.46"/>
                    <measurement group_id="O3" value="196.53" lower_limit="136.90" upper_limit="282.13"/>
                    <measurement group_id="O4" value="332.98" lower_limit="209.95" upper_limit="528.11"/>
                    <measurement group_id="O5" value="358.67" lower_limit="245.43" upper_limit="524.16"/>
                    <measurement group_id="O6" value="376.48" lower_limit="256.43" upper_limit="552.75"/>
                    <measurement group_id="O7" value="364.40" lower_limit="212.16" upper_limit="625.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 361 (n= 18, 19, 20, 19, 20, 17, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.17" lower_limit="53.72" upper_limit="99.68"/>
                    <measurement group_id="O2" value="159.37" lower_limit="110.50" upper_limit="229.87"/>
                    <measurement group_id="O3" value="186.26" lower_limit="129.59" upper_limit="267.70"/>
                    <measurement group_id="O4" value="309.01" lower_limit="196.87" upper_limit="485.03"/>
                    <measurement group_id="O5" value="298.08" lower_limit="203.83" upper_limit="435.91"/>
                    <measurement group_id="O6" value="351.12" lower_limit="245.76" upper_limit="501.67"/>
                    <measurement group_id="O7" value="374.98" lower_limit="272.66" upper_limit="515.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-dose Geometric Mean Fold Rises (GMFRs) From Baseline of Serum Antibodies Against Respiratory Syncytial Virus (RSV) by Anti-Fusion Protein (F) Immunoglobulin G (IgG) Assay</title>
        <description>Anti F IgG antibodies were determined by a multiplex IgG assay developed on the Meso Scale discovery platform.</description>
        <time_frame>Day 29, 61, 91, 181, 271 and 361</time_frame>
        <population>Immunogenicity population included participants in the As-treated population who had no protocol deviation judged to have the potential to interfere with the generation or interpretation of an immune response, and had baseline and/or any post-baseline result. Here, &quot;n&quot; is number of participants analysed for this outcome measure at give time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo (sterile saline for human use from commercial source, liquid) by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>RSV sF 20 Microgram (mcg)</title>
            <description>Participants received single dose of 20 mcg RSV sF by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI7510 20 Microgram (mcg)</title>
            <description>Participants received single dose of MEDI7510 (20 mcg RSV sF with 2.5 mcg glucopyranosyl lipid A [GLA] + 2% weight per volume stable emulsion) by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>RSV sF 50 Microgram (mcg)</title>
            <description>Participants received single dose of 50 mcg RSV sF by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI7510 50 Microgram (mcg)</title>
            <description>Participants received single dose of MEDI7510 (50 mcg RSV sF with 2.5 mcg GLA in 2% weight per volume stable emulsion) by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>RSV sF 80 Microgram (mcg)</title>
            <description>Participants received single dose of 80 mcg RSV sF by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>MEDI7510 80 Microgram (mcg)</title>
            <description>Participants received single dose of MEDI7510 (80 mcg RSV sF with 2.5 mcg GLA in 2% weight per volume stable emulsion) by intramuscular injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Post-dose Geometric Mean Fold Rises (GMFRs) From Baseline of Serum Antibodies Against Respiratory Syncytial Virus (RSV) by Anti-Fusion Protein (F) Immunoglobulin G (IgG) Assay</title>
          <description>Anti F IgG antibodies were determined by a multiplex IgG assay developed on the Meso Scale discovery platform.</description>
          <population>Immunogenicity population included participants in the As-treated population who had no protocol deviation judged to have the potential to interfere with the generation or interpretation of an immune response, and had baseline and/or any post-baseline result. Here, &quot;n&quot; is number of participants analysed for this outcome measure at give time points.</population>
          <units>fold rise</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 29 (n= 24, 20, 20, 20, 20, 19, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02" lower_limit="0.98" upper_limit="1.06"/>
                    <measurement group_id="O2" value="8.06" lower_limit="4.51" upper_limit="14.41"/>
                    <measurement group_id="O3" value="10.15" lower_limit="6.91" upper_limit="14.91"/>
                    <measurement group_id="O4" value="12.07" lower_limit="6.29" upper_limit="23.14"/>
                    <measurement group_id="O5" value="12.39" lower_limit="8.20" upper_limit="18.74"/>
                    <measurement group_id="O6" value="13.21" lower_limit="7.59" upper_limit="22.99"/>
                    <measurement group_id="O7" value="21.02" lower_limit="14.42" upper_limit="30.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 61 (n= 24, 20, 20, 20, 20, 20, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.11" lower_limit="1.02" upper_limit="1.20"/>
                    <measurement group_id="O2" value="7.78" lower_limit="4.40" upper_limit="13.75"/>
                    <measurement group_id="O3" value="7.00" lower_limit="4.79" upper_limit="10.22"/>
                    <measurement group_id="O4" value="8.93" lower_limit="4.63" upper_limit="17.22"/>
                    <measurement group_id="O5" value="9.37" lower_limit="6.53" upper_limit="13.43"/>
                    <measurement group_id="O6" value="9.55" lower_limit="5.48" upper_limit="16.67"/>
                    <measurement group_id="O7" value="15.39" lower_limit="10.70" upper_limit="22.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 91 (n= 22, 20, 20, 19, 20, 19, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.11" lower_limit="1.01" upper_limit="1.22"/>
                    <measurement group_id="O2" value="6.74" lower_limit="3.96" upper_limit="11.47"/>
                    <measurement group_id="O3" value="5.63" lower_limit="3.92" upper_limit="8.08"/>
                    <measurement group_id="O4" value="7.87" lower_limit="4.16" upper_limit="14.89"/>
                    <measurement group_id="O5" value="7.54" lower_limit="5.28" upper_limit="10.75"/>
                    <measurement group_id="O6" value="7.84" lower_limit="4.43" upper_limit="13.86"/>
                    <measurement group_id="O7" value="12.58" lower_limit="8.88" upper_limit="17.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 181 (n= 23, 19, 20, 19, 20, 18, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.08" lower_limit="0.99" upper_limit="1.18"/>
                    <measurement group_id="O2" value="4.84" lower_limit="3.11" upper_limit="7.55"/>
                    <measurement group_id="O3" value="3.63" lower_limit="2.59" upper_limit="5.09"/>
                    <measurement group_id="O4" value="5.42" lower_limit="2.86" upper_limit="10.29"/>
                    <measurement group_id="O5" value="4.88" lower_limit="3.56" upper_limit="6.71"/>
                    <measurement group_id="O6" value="5.43" lower_limit="3.12" upper_limit="9.43"/>
                    <measurement group_id="O7" value="8.19" lower_limit="5.78" upper_limit="11.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 271 (n= 20, 20, 20, 19, 20, 17, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.04" lower_limit="0.94" upper_limit="1.15"/>
                    <measurement group_id="O2" value="3.77" lower_limit="2.54" upper_limit="5.60"/>
                    <measurement group_id="O3" value="3.03" lower_limit="2.19" upper_limit="4.19"/>
                    <measurement group_id="O4" value="4.46" lower_limit="2.48" upper_limit="8.02"/>
                    <measurement group_id="O5" value="3.84" lower_limit="2.92" upper_limit="5.03"/>
                    <measurement group_id="O6" value="4.14" lower_limit="2.40" upper_limit="7.12"/>
                    <measurement group_id="O7" value="5.12" lower_limit="3.31" upper_limit="7.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 361 (n= 18, 19, 20, 19, 20, 17, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" lower_limit="0.93" upper_limit="1.20"/>
                    <measurement group_id="O2" value="3.56" lower_limit="2.42" upper_limit="5.23"/>
                    <measurement group_id="O3" value="2.87" lower_limit="2.11" upper_limit="3.90"/>
                    <measurement group_id="O4" value="4.14" lower_limit="2.40" upper_limit="7.14"/>
                    <measurement group_id="O5" value="3.19" lower_limit="2.46" upper_limit="4.13"/>
                    <measurement group_id="O6" value="3.86" lower_limit="2.27" upper_limit="6.57"/>
                    <measurement group_id="O7" value="5.27" lower_limit="3.80" upper_limit="7.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Experience a Post-dose Seroresponse to Respiratory Syncytial Virus (RSV) by Anti-Fusion Protein (F) Immunoglobulin G (IgG) Assay</title>
        <description>Seroresponse defined as a greater than or equal to (&gt;=) 4-fold rise from baseline.</description>
        <time_frame>Day 29</time_frame>
        <population>Immunogenicity population included participants in the As-treated population who had no protocol deviation judged to have the potential to interfere with the generation or interpretation of an immune response, and had baseline and/or any post-baseline result.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo (sterile saline for human use from commercial source, liquid) by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>RSV sF 20 Microgram (mcg)</title>
            <description>Participants received single dose of 20 mcg RSV sF by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI7510 20 Microgram (mcg)</title>
            <description>Participants received single dose of MEDI7510 (20 mcg RSV sF with 2.5 mcg glucopyranosyl lipid A [GLA] + 2% weight per volume stable emulsion) by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>RSV sF 50 Microgram (mcg)</title>
            <description>Participants received single dose of 50 mcg RSV sF by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI7510 50 Microgram (mcg)</title>
            <description>Participants received single dose of MEDI7510 (50 mcg RSV sF with 2.5 mcg GLA in 2% weight per volume stable emulsion) by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>RSV sF 80 Microgram (mcg)</title>
            <description>Participants received single dose of 80 mcg RSV sF by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>MEDI7510 80 Microgram (mcg)</title>
            <description>Participants received single dose of MEDI7510 (80 mcg RSV sF with 2.5 mcg GLA in 2% weight per volume stable emulsion) by intramuscular injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experience a Post-dose Seroresponse to Respiratory Syncytial Virus (RSV) by Anti-Fusion Protein (F) Immunoglobulin G (IgG) Assay</title>
          <description>Seroresponse defined as a greater than or equal to (&gt;=) 4-fold rise from baseline.</description>
          <population>Immunogenicity population included participants in the As-treated population who had no protocol deviation judged to have the potential to interfere with the generation or interpretation of an immune response, and had baseline and/or any post-baseline result.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="19"/>
                <count group_id="O7" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.00" upper_limit="14.25"/>
                    <measurement group_id="O2" value="65.0" lower_limit="40.78" upper_limit="84.61"/>
                    <measurement group_id="O3" value="90.0" lower_limit="68.30" upper_limit="98.77"/>
                    <measurement group_id="O4" value="80.0" lower_limit="56.34" upper_limit="94.27"/>
                    <measurement group_id="O5" value="90.0" lower_limit="68.30" upper_limit="98.77"/>
                    <measurement group_id="O6" value="84.2" lower_limit="60.42" upper_limit="96.62"/>
                    <measurement group_id="O7" value="100.0" lower_limit="83.16" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-dose Geometric Mean Counts (GMCs) From Baseline of T Cell Response Against Respiratory Syncytial Virus (RSV) by RSV F Enzyme-Linked Immunospot (ELISPOT)</title>
        <description>The ELISPOT assay for F protein-specific gamma interferon-producing T cells was performed using RSV F peptides.</description>
        <time_frame>Baseline (Day 1), Day 8 and 29</time_frame>
        <population>Immunogenicity population included participants in ATP who had no protocol deviation judged to have potential to interfere with generation or interpretation of an immune response, and had baseline and/or any post-baseline result. Here, &quot;N&quot; and 'n' is number of participants analysed for this outcome measure and at given time points, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo (sterile saline for human use from commercial source, liquid) by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>RSV sF 20 Microgram (mcg)</title>
            <description>Participants received single dose of 20 mcg RSV sF by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI7510 20 Microgram (mcg)</title>
            <description>Participants received single dose of MEDI7510 (20 mcg RSV sF with 2.5 mcg glucopyranosyl lipid A [GLA] + 2% weight per volume stable emulsion) by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>RSV sF 50 Microgram (mcg)</title>
            <description>Participants received single dose of 50 mcg RSV sF by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI7510 50 Microgram (mcg)</title>
            <description>Participants received single dose of MEDI7510 (50 mcg RSV sF with 2.5 mcg GLA in 2% weight per volume stable emulsion) by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>RSV sF 80 Microgram (mcg)</title>
            <description>Participants received single dose of 80 mcg RSV sF by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>MEDI7510 80 Microgram (mcg)</title>
            <description>Participants received single dose of MEDI7510 (80 mcg RSV sF with 2.5 mcg GLA in 2% weight per volume stable emulsion) by intramuscular injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Post-dose Geometric Mean Counts (GMCs) From Baseline of T Cell Response Against Respiratory Syncytial Virus (RSV) by RSV F Enzyme-Linked Immunospot (ELISPOT)</title>
          <description>The ELISPOT assay for F protein-specific gamma interferon-producing T cells was performed using RSV F peptides.</description>
          <population>Immunogenicity population included participants in ATP who had no protocol deviation judged to have potential to interfere with generation or interpretation of an immune response, and had baseline and/or any post-baseline result. Here, &quot;N&quot; and 'n' is number of participants analysed for this outcome measure and at given time points, respectively.</population>
          <units>spot forming counts per 10^6 PBMCs</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="19"/>
                <count group_id="O7" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n= 22, 16, 18, 19, 18, 20, 20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.17" lower_limit="38.28" upper_limit="58.14"/>
                    <measurement group_id="O2" value="41.59" lower_limit="33.25" upper_limit="52.02"/>
                    <measurement group_id="O3" value="35.95" lower_limit="31.13" upper_limit="41.52"/>
                    <measurement group_id="O4" value="39.81" lower_limit="33.39" upper_limit="47.46"/>
                    <measurement group_id="O5" value="48.44" lower_limit="38.90" upper_limit="60.31"/>
                    <measurement group_id="O6" value="37.78" lower_limit="34.00" upper_limit="41.98"/>
                    <measurement group_id="O7" value="38.43" lower_limit="33.51" upper_limit="44.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 (n= 20, 20, 18, 17, 18, 15, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.01" lower_limit="34.29" upper_limit="49.05"/>
                    <measurement group_id="O2" value="62.63" lower_limit="45.02" upper_limit="87.15"/>
                    <measurement group_id="O3" value="88.72" lower_limit="53.16" upper_limit="148.06"/>
                    <measurement group_id="O4" value="80.25" lower_limit="54.70" upper_limit="117.74"/>
                    <measurement group_id="O5" value="115.88" lower_limit="66.23" upper_limit="202.76"/>
                    <measurement group_id="O6" value="88.59" lower_limit="51.63" upper_limit="152.01"/>
                    <measurement group_id="O7" value="310.22" lower_limit="179.10" upper_limit="537.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (n= 23, 16, 20, 19, 20, 19, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.91" lower_limit="32.90" upper_limit="50.88"/>
                    <measurement group_id="O2" value="39.93" lower_limit="33.04" upper_limit="48.25"/>
                    <measurement group_id="O3" value="60.30" lower_limit="42.19" upper_limit="86.19"/>
                    <measurement group_id="O4" value="69.36" lower_limit="48.95" upper_limit="98.29"/>
                    <measurement group_id="O5" value="91.15" lower_limit="60.37" upper_limit="137.62"/>
                    <measurement group_id="O6" value="77.13" lower_limit="52.38" upper_limit="113.56"/>
                    <measurement group_id="O7" value="54.74" lower_limit="33.43" upper_limit="89.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-dose Geometric Mean Fold Rises (GMFRs) of T Cell Response Against Respiratory Syncytial Virus (RSV) by RSV F Enzyme-Linked Immunospot (ELISPOT)</title>
        <description>The ELISPOT assay for F protein-specific gamma interferon-producing T cells was performed using RSV F peptides.</description>
        <time_frame>Day 8 and 29</time_frame>
        <population>Immunogenicity population included participants in ATP who had no protocol deviation judged to have potential to interfere with generation or interpretation of an immune response, and had baseline and/or any post-baseline result. Here, &quot;N&quot; and 'n' is number of participants analysed for this outcome measure and at given time points, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo (sterile saline for human use from commercial source, liquid) by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>RSV sF 20 Microgram (mcg)</title>
            <description>Participants received single dose of 20 mcg RSV sF by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI7510 20 Microgram (mcg)</title>
            <description>Participants received single dose of MEDI7510 (20 mcg RSV sF with 2.5 mcg glucopyranosyl lipid A [GLA] + 2% weight per volume stable emulsion) by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>RSV sF 50 Microgram (mcg)</title>
            <description>Participants received single dose of 50 mcg RSV sF by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI7510 50 Microgram (mcg)</title>
            <description>Participants received single dose of MEDI7510 (50 mcg RSV sF with 2.5 mcg GLA in 2% weight per volume stable emulsion) by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>RSV sF 80 Microgram (mcg)</title>
            <description>Participants received single dose of 80 mcg RSV sF by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>MEDI7510 80 Microgram (mcg)</title>
            <description>Participants received single dose of MEDI7510 (80 mcg RSV sF with 2.5 mcg GLA in 2% weight per volume stable emulsion) by intramuscular injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Post-dose Geometric Mean Fold Rises (GMFRs) of T Cell Response Against Respiratory Syncytial Virus (RSV) by RSV F Enzyme-Linked Immunospot (ELISPOT)</title>
          <description>The ELISPOT assay for F protein-specific gamma interferon-producing T cells was performed using RSV F peptides.</description>
          <population>Immunogenicity population included participants in ATP who had no protocol deviation judged to have potential to interfere with generation or interpretation of an immune response, and had baseline and/or any post-baseline result. Here, &quot;N&quot; and 'n' is number of participants analysed for this outcome measure and at given time points, respectively.</population>
          <units>fold rise</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8 (n= 20, 20, 18, 17, 18, 15, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" lower_limit="0.78" upper_limit="1.04"/>
                    <measurement group_id="O2" value="1.57" lower_limit="1.10" upper_limit="2.24"/>
                    <measurement group_id="O3" value="2.18" lower_limit="1.37" upper_limit="3.49"/>
                    <measurement group_id="O4" value="2.01" lower_limit="1.29" upper_limit="3.12"/>
                    <measurement group_id="O5" value="2.21" lower_limit="1.28" upper_limit="3.80"/>
                    <measurement group_id="O6" value="2.45" lower_limit="1.46" upper_limit="4.10"/>
                    <measurement group_id="O7" value="8.01" lower_limit="4.74" upper_limit="13.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (n= 23, 16, 20, 19, 20, 19, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" lower_limit="0.72" upper_limit="1.06"/>
                    <measurement group_id="O2" value="0.91" lower_limit="0.77" upper_limit="1.07"/>
                    <measurement group_id="O3" value="1.54" lower_limit="1.11" upper_limit="2.13"/>
                    <measurement group_id="O4" value="1.80" lower_limit="1.25" upper_limit="2.58"/>
                    <measurement group_id="O5" value="1.99" lower_limit="1.26" upper_limit="3.15"/>
                    <measurement group_id="O6" value="2.10" lower_limit="1.47" upper_limit="2.99"/>
                    <measurement group_id="O7" value="1.36" lower_limit="0.84" upper_limit="2.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Experience a Post-dose 3-fold Cell-mediated Immune Response to RSV F on Day 8</title>
        <description>Seroresponse defined as a greater than or equal to (&gt;=) 3-fold rise from baseline</description>
        <time_frame>Day 8</time_frame>
        <population>Immunogenicity population included participants in the As-treated population who had no protocol deviation judged to have the potential to interfere with the generation or interpretation of an immune response, and had baseline and/or any post-baseline result.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo (sterile saline for human use from commercial source, liquid) by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>RSV sF 20 Microgram (mcg)</title>
            <description>Participants received single dose of 20 mcg RSV sF by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>MEDI7510 20 Microgram (mcg)</title>
            <description>Participants received single dose of MEDI7510 (20 mcg RSV sF with 2.5 mcg glucopyranosyl lipid A [GLA] + 2% weight per volume stable emulsion) by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>RSV sF 50 Microgram (mcg)</title>
            <description>Participants received single dose of 50 mcg RSV sF by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>MEDI7510 50 Microgram (mcg)</title>
            <description>Participants received single dose of MEDI7510 (50 mcg RSV sF with 2.5 mcg GLA in 2% weight per volume stable emulsion) by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>RSV sF 80 Microgram (mcg)</title>
            <description>Participants received single dose of 80 mcg RSV sF by intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>MEDI7510 80 Microgram (mcg)</title>
            <description>Participants received single dose of MEDI7510 (80 mcg RSV sF with 2.5 mcg GLA in 2% weight per volume stable emulsion) by intramuscular injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experience a Post-dose 3-fold Cell-mediated Immune Response to RSV F on Day 8</title>
          <description>Seroresponse defined as a greater than or equal to (&gt;=) 3-fold rise from baseline</description>
          <population>Immunogenicity population included participants in the As-treated population who had no protocol deviation judged to have the potential to interfere with the generation or interpretation of an immune response, and had baseline and/or any post-baseline result.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="15"/>
                <count group_id="O7" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.00" upper_limit="17.65"/>
                    <measurement group_id="O2" value="12.5" lower_limit="1.55" upper_limit="38.35"/>
                    <measurement group_id="O3" value="18.8" lower_limit="4.05" upper_limit="45.65"/>
                    <measurement group_id="O4" value="25.0" lower_limit="7.27" upper_limit="52.38"/>
                    <measurement group_id="O5" value="35.3" lower_limit="14.21" upper_limit="61.67"/>
                    <measurement group_id="O6" value="46.7" lower_limit="21.27" upper_limit="73.41"/>
                    <measurement group_id="O7" value="73.7" lower_limit="48.80" upper_limit="90.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs were collected from informed consent through Day 28 post dose; SAEs from informed consent through Days 28 and 361; treatment emergent adverse events of special interest and new onset chronic diseases through the Day 361 visit.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received placebo (sterile saline for human use from commercial source, liquid) by intramuscular injection on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>RSV sF 20 Microgram (mcg)</title>
          <description>Participants received single dose of 20 mcg RSV sF by intramuscular injection on Day 1.</description>
        </group>
        <group group_id="E3">
          <title>MEDI7510 20 Microgram (mcg)</title>
          <description>Participants received single dose of MEDI7510 (20 mcg RSV sF with 2.5 mcg glucopyranosyl lipid A [GLA] + 2% weight per volume stable emulsion) by intramuscular injection on Day 1.</description>
        </group>
        <group group_id="E4">
          <title>RSV sF 50 Microgram (mcg)</title>
          <description>Participants received single dose of 50 mcg RSV sF by intramuscular injection on Day 1.</description>
        </group>
        <group group_id="E5">
          <title>MEDI7510 50 Microgram (mcg)</title>
          <description>Participants received single dose of MEDI7510 (50 mcg RSV sF with 2.5 mcg GLA in 2% weight per volume stable emulsion) by intramuscular injection on Day 1.</description>
        </group>
        <group group_id="E6">
          <title>RSV sF 80 Microgram (mcg)</title>
          <description>Participants received single dose of 80 mcg RSV sF by intramuscular injection on Day 1.</description>
        </group>
        <group group_id="E7">
          <title>MEDI7510 80 Microgram (mcg)</title>
          <description>Participants received single dose of MEDI7510 (80 mcg RSV sF with 2.5 mcg GLA in 2% weight per volume stable emulsion) by intramuscular injection on Day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Staphylococcal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Heat exhaustion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Injection site haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Periorbital haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Intraocular pressure increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Penile pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hyperkeratosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Judith Falloon, MD</name_or_title>
      <organization>MedImmune, LLC</organization>
      <phone>301-398-5000</phone>
      <email>falloonj@medimmune.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

